Despite established benefits, treatment intensification, combining androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPi) and/or chemotherapy, is underutilized in metastatic prostate cancer settings prior to metastatic castration-resistant prostate cancer (mCRPC). This underutilization impacts subsequent first-line (1L) treatment patterns and clinical outcomes in patients with mCRPC, as evidenced by recent real-world analyses.1,2

Treatment intensification, defined as the combination of androgen deprivation therapy (ADT) with an androgen receptor pathway inhibitor (ARPi) and/or chemotherapy, has demonstrated clinical benefit over ADT-only regimens in prostate cancer settings preceding metastatic castration-resistant prostate cancer (mCRPC).1,2 However, real-world data from the United States indicates that this strategy is not consistently applied.1,2

Real-World Analysis of Treatment Patterns

A real-world analysis assessed the rates of treatment intensification before the mCRPC setting, first-line (1L) treatment patterns in mCRPC, and clinical outcomes in patients with mCRPC in the United States.1 The study included patients diagnosed with mCRPC between January 1, 2015, and December 31, 2020, who had received at least one line of systemic therapy for mCRPC.1 Patients were stratified based on whether they received prior treatment intensification (TI) or ADT-only treatment before mCRPC.1

The analysis identified 2,732 patients with mCRPC. Of these, 1,059 patients (38.8%) had received prior TI, while 1,673 patients (61.2%) had received ADT-only treatment before mCRPC.1 In the 1L mCRPC setting, patients who had received prior TI were more likely to receive chemotherapy (42.0% vs 28.9%) or an ARPi (38.0% vs 31.0%) compared to those who had received ADT-only.1

The study found that patients who received prior TI had improved overall survival (OS) in the mCRPC setting compared to those who received ADT-only (median OS: 26.0 months vs 20.0 months; HR 0.72, 95% CI 0.63-0.82, p < 0.0001).1 Similar trends were observed for time to next treatment (TTNT) and time to chemotherapy (TTCT), with patients receiving prior TI demonstrating longer durations (median TTNT: 10.0 months vs 7.0 months; HR 0.72, 95% CI 0.65-0.80, p < 0.0001; median TTCT: 18.0 months vs 12.0 months; HR 0.72, 95% CI 0.64-0.80, p < 0.0001).1

Another real-world analysis explored barriers and facilitators to treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC).2 This study also highlighted the underutilization of treatment intensification, despite its established benefits in improving survival outcomes in mCSPC.2 The findings from both studies underscore a gap between evidence-based guidelines and real-world clinical practice.1,2

Clinical Implications

The persistent underutilization of treatment intensification in metastatic prostate cancer, particularly before the mCRPC stage, represents a clear disconnect between established evidence and clinical practice. The data from Swami et al. and Loeb et al. unequivocally demonstrate that patients who receive prior treatment intensification experience superior overall survival and delayed progression in the mCRPC setting. This is not a subtle difference; a 6-month median OS advantage is substantial and directly impacts patient prognosis. It suggests that many patients are not receiving optimal care at critical junctures in their disease trajectory.

For clinicians, these findings should prompt a re-evaluation of current prescribing habits. The National Comprehensive Cancer Network (NCCN) guidelines, among others, advocate for treatment intensification in mCSPC. The observed rates of ADT-only treatment prior to mCRPC indicate that these recommendations are not being universally implemented. Barriers identified in studies, such as physician inertia, patient comorbidities, or perceived toxicity, must be actively addressed. The long-term benefits of early intensification, including improved OS and delayed need for subsequent therapies, outweigh the short-term complexities.

From an industry perspective, the underutilization of ARPIs and chemotherapy in earlier stages means that the full clinical potential of these agents is not being realized across the patient population. This also implies a missed opportunity for improved patient outcomes and potentially broader market penetration for these established therapies. Education initiatives, both from professional bodies and pharmaceutical companies, must focus on reinforcing the long-term survival advantages of early intensification to bridge this evidence-practice gap. Ultimately, ensuring that more patients receive appropriate, guideline-concordant care earlier in their disease course is paramount.

Key Takeaways
  • The Pivot Real-world data reveals suboptimal rates of treatment intensification before mCRPC.
  • The Data Patients receiving prior treatment intensification had improved overall survival (OS) in the mCRPC setting (HR 0.72, 95% CI 0.63-0.82, p < 0.0001).1
  • The Action Clinicians should evaluate current prescribing practices to ensure appropriate treatment intensification in earlier stages of metastatic prostate cancer.

ART-2026-403

06/26

Save as PDF
Reviewed & published by
Editorial Team
Cite This Article

Team TLSFE. Treatment intensification underutilized in metastatic prostate cancer. The Life Science Feed. Updated June 17, 2026. Accessed June 17, 2026. https://thelifesciencefeed.com/oncology/prostatic-neoplasms/insights/treatment-intensification-underutilized-in-metastatic-prostate-cancer.

Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Medical Disclaimer

The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

References

1. Swami U, Agarwal N, Thompson A. Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States. Clin Genitourin Cancer. 2026.

2. Loeb S, Agarwal N, El-Chaar N. Barriers and Facilitators of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer. JAMA Netw Open. 2025.